Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics


Kori M., ARGA K. Y.

Expert Review of Anticancer Therapy, cilt.22, sa.11, ss.1211-1224, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 22 Sayı: 11
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/14737140.2022.2139681
  • Dergi Adı: Expert Review of Anticancer Therapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Chemical Abstracts Core, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1211-1224
  • Anahtar Kelimeler: Epstein-Barr virus, Hepatitis B and C virus, Human Herpesvirus 8, Human Papillomaviruses, Human T-cell lymphotropic virus 1, protein biomarkers
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Introduction: Although the idea that carcinogenesis might be caused by viruses was first voiced about 100 years ago, today’s data disappointingly show that we have not made much progress in preventing and/or treating viral cancers in a century. According to recent studies, infections are responsible for approximately 13% of cancer development in the world. Today, it is accepted and proven by many authorities that Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 8 (HHV8), Human T-cell Lymphotropic virus 1 (HTLV1) and highly oncogenic Human Papillomaviruses (HPVs) cause or/and contribute to cancer development in humans. Areas covered: Considering the insufficient prevention and/or treatment strategies for viral cancers, in this review we present the current knowledge on protein biomarkers of oncogenic viruses. In addition, we aimed to decipher their potential for clinical use by evaluating whether the proposed biomarkers are expressed in body fluids, are druggable, and act as tumor suppressors or oncoproteins. Expert opinion: Consequently, we believe that this review will shed light on researchers and provide a guide to find remarkable solutions for the prevention and/or treatment of viral cancers.